"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 3 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 4 | 1 | 5 |
| 2003 | 6 | 8 | 14 |
| 2004 | 4 | 6 | 10 |
| 2005 | 10 | 8 | 18 |
| 2006 | 4 | 6 | 10 |
| 2007 | 8 | 9 | 17 |
| 2008 | 5 | 4 | 9 |
| 2009 | 10 | 6 | 16 |
| 2010 | 2 | 5 | 7 |
| 2011 | 6 | 2 | 8 |
| 2012 | 9 | 4 | 13 |
| 2013 | 6 | 3 | 9 |
| 2014 | 5 | 6 | 11 |
| 2015 | 1 | 7 | 8 |
| 2016 | 3 | 6 | 9 |
| 2017 | 4 | 6 | 10 |
| 2018 | 3 | 2 | 5 |
| 2019 | 5 | 3 | 8 |
| 2020 | 1 | 5 | 6 |
| 2021 | 1 | 4 | 5 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N, Galazka A. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5?years: a plain language summary. Neurodegener Dis Manag. 2022 12; 12(6):303-310.
-
Zorzetti N, Lauro A, Khouzam S, Marino IR. Immunosuppression, Compliance, and Tolerance After Orthotopic Liver Transplantation: State of the Art. Exp Clin Transplant. 2022 03; 20(Suppl 1):3-9.
-
Ravindranath MH, El Hilali F, Filippone EJ. The Impact of Inflammation on the Immune Responses to Transplantation: Tolerance or Rejection? Front Immunol. 2021; 12:667834.
-
Fromal OV, Swaminathan V, Soares RR, Ho AC. Recent advances in diagnosis and management of sympathetic ophthalmia. Curr Opin Ophthalmol. 2021 Nov 01; 32(6):555-560.
-
Martinez Cantarin MP. Diabetes in Kidney Transplantation. Adv Chronic Kidney Dis. 2021 11; 28(6):596-605.
-
Vuille-Lessard ?, Montani M, Bosch J, Semmo N. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J Autoimmun. 2021 09; 123:102710.
-
Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece IK, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021 07 22; 138(3):273-282.
-
Han YS, Mehta AM, Lee TC, Nagiel A, Pulido JS. Diagnostic and Therapeutic Challenges. Retina. 2020 Aug; 40(8):1641-1643.
-
Shohat N, Goswami K, Tan TL, Yayac M, Soriano A, Sousa R, Wouthuyzen-Bakker M, Parvizi J. 2020 Frank Stinchfield Award: Identifying who will fail following irrigation and debridement for prosthetic joint infection. Bone Joint J. 2020 Jul; 102-B(7_Supple_B):11-19.
-
Pai S, Kramer N, Rosenstein ED. Malignant Catatonia as the Presenting Manifestation of Systemic Lupus Erythematosus. Bull Hosp Jt Dis (2013). 2020 Jun; 78(2):146-152.